Valuation: Design Therapeutics, Inc.

Market Cap 783M 678M 641M 582M 1.09B 75.07B 1.1B 7.65B 2.96B 38.08B 2.94B 2.87B 121B P/E 2026 *
-9.14x
P/E 2027 * -7.81x
Enterprise Value 806M 699M 661M 600M 1.12B 77.36B 1.13B 7.89B 3.05B 39.24B 3.03B 2.96B 125B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
68.13%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Design Therapeutics, Inc.

1 day+0.64%
1 week-15.07%
Current month-16.70%
1 month-16.75%
3 months+5.36%
6 months+13.86%
Current year+34.01%
1 week 12.16
Extreme 12.16
15.14
1 month 12.16
Extreme 12.16
16.12
Current year 8.23
Extreme 8.23
17.25
1 year 5.28
Extreme 5.28
17.25
3 years 1.96
Extreme 1.96
17.25
5 years 1.94
Extreme 1.94
26.3
10 years 1.94
Extreme 1.94
50.5
Manager TitleAgeSince
Chief Executive Officer 56 2023-08-24
Chief Tech/Sci/R&D Officer 60 2025-04-16
Chief Tech/Sci/R&D Officer - 2025-01-31
Director TitleAgeSince
Chairman 56 2017-12-17
Director/Board Member 71 2019-06-30
Director/Board Member 49 2020-01-31
Date Insider Type Main position Quantity % Market Cap. Importance
3/31/26 Free

Director

67,500 0.1185%
1/2/26 Free

Chief Executive Officer

750,000 1.3166%
1/2/26 Free

Director

45,000 0.0790%
Change 5-day change 1-year change 3-year change Capi.($)
+0.60%-15.07%+111.26%+392.94% 783M
+1.30%+1.79%-0.22%+28.35% 45.91B
+1.44%+5.82%+45.84%+30.05% 44.25B
+1.62%-1.87%+355.49%+545.17% 41.99B
+1.19%+2.99%+5.97%+68.50% 39.58B
+1.75%-1.53%+12.22%+41.11% 31.08B
+0.76%+6.45%+24.69%+127.30% 17.21B
-3.17%-8.82% - - 16.27B
+2.65%+8.04%+22.05%+39.26% 14.96B
-0.82%+4.13%-1.53%-34.41% 13.42B
Average +0.72%-0.29%+63.97%+137.59% 26.55B
Weighted average by Cap. +1.08%+0.63%+73.77%+128.97%

Financials

2026 *2027 *
Net sales - -
Net income -86.04M -74.57M -70.48M -63.98M -120M -8.25B -121M -841M -325M -4.19B -323M -316M -13.34B -115M -99.66M -94.2M -85.52M -160M -11.03B -161M -1.12B -435M -5.6B -432M -422M -17.84B
Net Debt 23.81M 20.64M 19.5M 17.71M 33.19M 2.28B 33.38M 233M 89.97M 1.16B 89.45M 87.46M 3.69B -295M -256M -242M -219M -411M -28.31B -414M -2.89B -1.12B -14.36B -1.11B -1.08B -45.77B
Logo Design Therapeutics, Inc.
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Employees
55
Date Price Change Volume
26-09-17 US$12.58 +0.56% 100,326
26-09-16 US$12.51 +2.29% 985,135
26-09-15 US$12.23 -9.58% 1,280,373
26-09-14 US$13.52 -7.59% 1,256,897
26-09-11 US$14.63 -1.15% 715,238
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
12.50USD
Average target price
21.00USD
Spread / Average Target
+67.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DSGN Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!